Abstract [ 11 C]Ro15-4513 has been introduced as a positron emission tomography radioligand to image the GABA A a5 receptor subtype thought to be important in learning, memory and addiction. However, the in vivo selectivity of the ligand remains unknown and a full assessment of different analysis approaches has yet to be performed. Using human heterologous competition data, with [
Introduction g-Aminobutyric acid (GABA) is the most abundant and influential inhibitory neurotransmitter in the brain. Investigation of the GABA system in humans in vivo has been made possible, through the development of radioligands selective for the allosteric benzodiazepine site on the GABA A receptor, with positron emission tomography (PET). PET radioligands for the benzodiazepine site have been developed with good brain penetration, specific binding and reversible kinetics, though in most cases with a degree of non-selectivity for GABA A receptor subtypes. The best known example is [ ]flumazenil means that the PET signal is a composite of the local subtype concentrations, which vary regionally and between clinical populations. The heterogeneous regional distribution of the different benzodiazepine-sensitive GABA A subtypes, as well as their markedly different functional roles, has led to the search for more selective ligands. The extrasynaptic GABA A a5 receptor has been of particular interest due to its putative role in learning, memory and addiction.
The imidazodiazepine Ro15-4513 is a partially selective inverse-agonist for the GABA A a5 receptor, developed in the 1980s by Roche for the labelling of benzodiazepine sites and therefore, by allosteric interaction, the GABA/benzodiazepine complex. 1 Originally applied for visualisation of receptor sites in the rodent brain, 2 Ro15-4513 later epitomised the concept of inverse agonism after demonstrating inhibition of the behavioural intoxication effects of ethanol. 3, 4 When labelled with carbon-11, Ro15-4513 has been used as a PET radioligand to enable investigation of the GABA A a5 receptor subtype and its dysregulation in a number of disorders including addiction. However, whilst kinetic analysis methods have been developed previously in order to try to isolate the GABA A a5 component of the signal, 5, 6 the true in vivo selectivity of [ 11 C]Ro15-4513 and the magnitude of the GABA A a5 specific signal have yet to be fully characterised in vivo in man.
Autoradiography studies confirm that [ 11 C]Ro15-4513 has partial selectivity for the GABA A a5 receptor subtype, with an affinity, K i , approximately 20-fold greater over the other GABA A subtypes ($10 nM GABA A a1,2,3; $0.5 nM GABA A a5). 7, 8 The high proportion of a5-specific signal, and its subcortical localisation, were demonstrated using the highly selective ligands RY80 and L655,708 in the rat, 9 though it has also been suggested that there is some binding to the benzodiazepine-insensitive GABA A subtypes GABA A a4 and GABA A a6, shown with high concentrations of diazepam and GABA. 10 A portion of cerebellum binding of [ 11 C]Ro15-4513 has been shown to be displaceable by the benzodiazepines flumazenil and clonazepam both in vitro and in vivo in non-human primates and humans. 11, 12 Furthermore, the relatively high concentrations of GABA A a1,2,3 demonstrated by autoradiography, particularly in the cortex and cerebellum, 13 suggest that despite a lower relative affinity, there will be some measurable signal from these sites due to a greater B max .
To date, quantification of dynamic [ 11 C]Ro15-4513 PET data in non-human primates and humans has been undertaken in several ways. Initial validation of the ligand involved homologous and heterologous competition studies with clonazepam in non-human primates. 11, 14 These studies identified regions of the brain in which heterologous and homologous blockade differs, suggesting that [ 11 C]Ro15-4513 has specific binding targets not including those of other nonselective benzodiazepine agents. In humans, 2TCM quantification of V T revealed a pattern of differing tissue kinetics, suggesting regionally heterogeneous binding. 15 Similarly, application of spectral analysis for parametric mapping of [ 11 C]Ro15-4513 V T in humans in vivo, identified its primarily limbic distribution. 9 The relatively low signal in the white matter, particularly the pons, suggested that this might be a suitable reference region for methods such as the simplified reference tissue model (SRTM), to avoid arterial sampling. 16 The presence of low signal alone is not sufficient to validate the region as an appropriate reference region and thus this method could underestimate target binding with some level of bias. 17, 18 Using [ 11 C]flumazenil, for example, application of SRTM with the pons as a reference tissue performed poorly in test-retest and in clinical identification of hippocampal sclerosis. 19, 20 Given the proposed lack of GABA A a5 in the cerebellum, this provides an alternative candidate reference region for investigation.
To fully characterise both the selectivity of [ 11 C]Ro15-4513 for the GABA A a5 subtype and evaluate whether there is a suitable reference tissue devoid of specific binding, heterologous competition studies with a selective GABA A a5 compound are required. We were provided access to a dataset previously acquired by F. Hoffmann-La Roche consisting of dynamic [
11 C]Ro15-4513 PET data measured in healthy human subjects following a range of doses of the highly selective GABA A a5 selective negative allosteric modulator Basmisanil. 21, 22 In this article, we use these heterologous competition data to: (a) elucidate the true regional in vivo selectivity of [
11 C]Ro15-4513 for the GABA A a5 receptor, (b) assess the validity of the cerebellum and pons as reference tissues and (c) evaluate the merits of different analytical techniques for quantifying GABA A a5 receptor availability from a dynamic [
11 C]Ro15-4513 PET scan.
Materials and methods

Data set
Data were taken from a PET study commissioned by F. Hoffmann-La Roche (Basel, Switzerland), which was performed by Hammersmith Imanet (Hammersmith, London, UK). The study was approved by the London-Brent research ethics committee, by the UK Administration of Radioactive Substances Advisory Committee and conducted under ICH GCP guidelines. The study from which our dataset is drawn aimed to evaluate receptor occupancy, which is not reported here.
Ten healthy male volunteers, who had provided informed consent, underwent three [
11 C]Ro15-4513 PET scans, one at baseline and two, at 3 and 9 h, following the administration of one of four separate doses (2 Â 15 mg, 2 Â 60 mg, 3 Â 130 mg, 3 Â 1250 mg) of the a5-selective negative allosteric modulator Basmisanil. Unavailability of baseline scan data for one subject led to this subject being excluded from our analyses. The brain was initially extracted from the T1-weighted MR image. Frame-by-frame motion correction of the dynamic PET data was performed using mutual information co-registration of the individual frames to a reference frame (frame 16). An average motion-corrected PET image was generated and used for co-registration with the extracted T1-weighted MR brain image. The CIC neuroanatomical atlas 24 was non-linearly registered to the individual's extracted brain, via non-linear registration of the T1 anatomical images, to generate a personalised set of anatomically parcellated regions. Finally, regional tissue time-activity curves (TACs) were generated from this parcellation for a set of regions of interest (ROI) with varying signal strengths and GABA A a5 density; insular cortex, anterior cingulate, cingulate cortex, occipital lobe, temporal lobe, parietal lobe, frontal lobe, parahippocampal gyrus, cerebellum, nucleus accumbens, hippocampus, amygdala, caudate, putamen, thalamus, midbrain, medulla, pons.
The total plasma radioactivity was estimated by multiplying the whole blood radioactivity time course by a sigmoid model (equation (1)) that had been fitted to the discrete plasma:blood (POB) ratio. The parent plasma arterial input function was then generated by multiplying these data with a continuous estimate of the parent fraction. The parent fraction data were fit to the same sigmoid equation (1) .
where Y is the estimated POB or parent fraction, t is time and a, b, c, d are parameters estimated by a nonlinear least-squares curve fit. The resulting plasma arterial input function was then smoothed post peak using a tri-exponential fit. A delay correction was performed for each scan to account for any temporal delay between blood sample measurement and the tomographic measurements of the tissue data. One (1TCM) and two (2TCM) tissue compartment plasma input models were fitted to the regional PET time activity data, with a fitted blood volume term, to identify an appropriate kinetic model and to subsequently derive estimates of V T for each ROI. All tissue and input function measurements were corrected for radioactive decay.
Data analysis: [
11 C]Ro15-4513 specific binding and selectivity V T values obtained from the 2TCM were analysed, across all subjects and doses for the 18 ROIs, using a single-site competition model (see equation (2)). were both fixed to the values derived from the ROI analysis. Parametric maps of V T were generated for each scan in a two-stage process; first, a basis function 1TCM parametric imaging routine was employed because of its robustness to noise, and second, the 1TCM bias was corrected by applying the regression factor derived from the 1TCM vs. 2TCM regional regression analysis to obtain corrected 2TCM
These images were then non-linearly registered into MNI space, using the structural T1 data to derive appropriate non-linear deformation parameters.
Finally, the basis function implementation of equation (2) and a unity basis term for V voxel X ) was fitted to these data at each voxel using a non-negative least-squares algorithm to generate parametric images of V 5 and V x . Method I (2TCM -V T ). V T was derived from the 2TCM. In more detail, the time-activity curves were fitted by a convolution of the arterial plasma parent input function with an impulse response function comprising a sum of two exponentials, with a fitted blood volume (see equation (5)).
where C PET t ð Þ is the measured PET radioactivity data at time-point t, V B is the estimated blood volume, C B is the concentration of radioactivity in whole blood, C P is the concentration of radioactivity in the plasma, and and represent functions of the microparameters (K 1 , k 2 , k 3 k 4 ), substituted for clarity. 26 At equilibrium, the ratio of parent tissue to plasma concentration of radioactivity is the total volume of distribution (or partition coefficient), V T , which can be calculated as,
Method II (2TCM -V S ). V S , the volume of distribution of the second tissue compartment in the 2TCM, was estimated from the individual rate constants obtained from the 2TCM fit according to,
Method III (spectral analysis -V 5 ). Previously, spectral partitioning of the [ 11 C]Ro15-4513 kinetic components using spectral analysis 27 has been proposed as a method to estimate V 5 directly. 5, 6 One hundred exponential functions were generated, with the decay parameter logarithmically distributed between 0.00006371 and 1 s À1 , 28 and convolved with the arterial parent plasma input function to generate a set of kinetic basis functions. A non-negative least-squares algorithm was then used to fit this over-complete basis set to the measured data.
subject to i ! 0: A bandpass approach was used based on the slow kinetic component seen in high GABA A a5 density regions, and the zolpidem-induced reduction in the fast kinetic components of the spectrum. 6 Thus, an integral of the slow kinetic component of the spectrum has been hypothesised to relate to GABA A a5 binding, and V 5 is estimated according to equation (9) . The slow component band was defined by the limits a ( ¼ 0.00006371 s À1 ) and b (¼ 0.001 s À1 ).
Method IV (SRTM -BP ND ). BP ND was estimated using the simplified reference tissue model (SRTM) with both the cerebellum and pons as alternative reference tissues. 29 The basis function implementation of SRTM was used for parameter estimation,
where C R is the measured radioactivity concentration in the reference tissue, B i is a basis function comprising a convolution of C R and an exponential and 1,2 are parameters used to derive BP ND , R 1 and k 2 .
For each of the four analysis methods, the relationship between the outcome measure and the gold standard V 5 was assessed using linear regression and the Pearson's square of residuals, R 2 .
Results
The results from fitting the 1TCM and 2TCM models to the 18 chosen ROIs are given in Table 1 . In almost all regions, the 2TCM performed better according to the Akaike information criterion, with the four regions for which the two models performed equally well being the four with the lowest specific signal, as expected. The 2TCM was therefore chosen as the best model to describe the radioligand kinetics across the brain, and compartmental modelling parameters quoted henceforth are derived using 2TCM. K 1 is high and relatively constant across the brain ($0.4 ml cm 3 min À1 ) consistent with a single pass extraction of at least 50%. No effect of drug was seen on K 1 in any region (Student's t-test: t < 0.55, p > 0.64 in all ROIs). Examples of 2TCM fits in the cerebellum, a region largely devoid of GABA A a5, and the temporal lobe, frontal lobe and hippocampus, where density is high, are given in Figure 1 .
A competition binding model accounting for the selective modulator Basmisanil was fitted to all 18 ROIs. Examples of model fits from four representative regions are given in Figure 2 . In each case, a good fit was obtained along with a corresponding estimate of V 5 in each region (see Table 1 ). Ninety-five percent confidence intervals for each parameter estimate in each region are calculated and shown in Table 1 . There was no evidence of any significant displaceable GABA A a5 signal in either the cerebellum or pons, whereas the other regions showed a clear dose dependent reduction in V T with increasing doses of Basmisanil.
Optimisation of V ND using the regional [ Table 1 ). Parametric images of [ 11 C]Ro15-4513 V T along with the specific V 5 and V x volumes of distribution are displayed in Figure 5 . Consistent with preclinical data on GABA A a5, highest V T is seen in subcortical limbic structures including the nucleus accumbens and hippocampus, as well as the anterior cingulate and insula. Low signal is seen in the striatum, cerebellum and brainstem. The V 5 images confirm this distribution, and maps of V x are similar to V T images obtained with [ 11 C]flumazenil. Images of the percentage specific signal attributable to V 5 demonstrate the high GABA A a5 subcortical signal, decreasing into the cortex and lowest in the occipital cortex, cerebellum and brainstem.
The results from the heterologous competition data then allowed for an assessment of the performance of four different analysis approaches that have been previously applied to [ 11 C]Ro15-4513, in the absence of 
Discussion
A full characterisation of [ 11 C]Ro15-4513 in humans using heterologous competition data has been presented that allows for the determination of the GABA A a5 specific binding signal, as well as an estimate of the remaining GABA A sub-type specific binding and non-displaceable signal across the brain. This provides important information to help with the interpretation of previous clinical studies employing 11 C]Ro15-4513 PET data used in our analysis included scans performed at baseline and following the administration of an a5-selective negative allosteric modulator (RG1662). Using competition data obtained across a range of different doses allowed us to isolate the specific binding component of the total volume of distribution that corresponds to GABA A a5 by applying an appropriate competition binding model. The remaining portion of the V T was partitioned into the non-displaceable and remaining GABA A subtype binding using [ 11 C]flumazenil data obtained from the literature.
Our approach allowed careful validation of different approaches for quantification of GABA A a5 density, not possible before. Given that most studies using this radioligand will be undertaken in the absence of competitive blockade, it is important to understand the regional selectivity of [
11 C]Ro15-4513 and the limitations of different analysis approaches that attempt to quantify GABA A a5 binding.
The 2TCM was identified as the optimal tracer kinetic model to describe the kinetics of [
11 C]Ro15-4513 based on the Akaike information criteria. This is consistent with previous model identification analyses performed for this tracer.
6,9,28 V T was greatest in the nucleus accumbens, anterior cingulate gyrus and amygdala, regions also found to have the greatest proportions of a5-specific signal contribution. Regions with relatively low a5-specific binding were found to be equally well fitted using a 1TCM model. Subcortical regions, such as the striatum, including the putamen and caudate nuclei, despite their relatively low total V T , display a relatively greater proportion of a5-specific signal as compared with the cortical structures. This proportion of a5-specific signal demonstrates good, but not complete, selectivity for the subtype, with an average of 66% of the specific signal across all measured regions, including low-signal regions such as the cerebellum.
Comparing the different analysis methods against the gold standard GABA A a5 data in this cohort of healthy human subjects showed that V T derived from 2TCM has a good linear relationship with GABA A a5 specific binding, consistent with GABA A a5 representing a significant portion of the specific binding in most regions considered although its use requires interpreting an outcome measure that contains a degree of non-selective binding. While inferences may be made regionally, there will not be any absolute certainty of the source of any change or difference in signal, from GABA A a5 or any other subtype.
V S , derived from the 2TCM, has a non-linear relationship with V 5 , and a higher variance, with regions of lower signal underestimated and those of higher signal overestimated. Thus, whilst trying to more accurately quantify the exact level of GABA A a5 specific binding, this method ends up having significant bias and variance. This is not unexpected given the challenge of having to both try to kinetically partition the data and rely on the interpretation that the second tissue compartment contains only a5 specific binding. Even for radioligands that bind selectively to only one target, it has been shown previously that the direct estimation of these parameters is challenging and the most robust use of this type of method involves subtracting the V ND obtained from a reference region off the V T to obtain V S instead. 29 The V 5 derived from bandpass spectral analysis relies on being able to separate the component corresponding to the specific a5 signal purely from the kinetics. This is inherently very difficult because there are components due to free and non-specific binding in addition to the a5 and non-a5 specific components. Thus, even if one is able to separate the two specific components, it is not clear how the non-displaceable component is attributed. Further, the kinetic partitioning of PET data is easily influenced by noise, subject motion, and inaccuracies in corrections such as scatter. Thus, it is very challenging to try and estimate the specific a5 component this way and therefore it is not surprising that the SA method suffers from inaccuracies. This is analogous to the challenges of directly estimating the BP ND from direct estimates of k 3 over k 4 in the 2TCM where again kinetic partitioning is required. 29 The performance of both these methods is further evidence that kinetic partitioning methods are not the primary methods of choice.
Finally, the application of SRTM using the cerebellum or pons provides a linear relationship with the true GABA A a5 binding. For cortical regions, the cerebellum reference region with its increased statistics from a larger region and similar levels of off target non-selective binding may be most appropriate. In particular, given that without a homologous competition study, it has been necessary to make the assumption that V ND is equal across all regions, for occupancy studies, it makes most sense to use a cerebellum reference region and cortical estimates of occupancy, as they are not dependent on this assumption. The use of a cerebellum reference to quantify sub-cortical structures is more questionable with differing levels of off target binding present. In this context, it should be noted that the non-displaceable denominator in BP ND also contains the off target specific binding term and should also be accounted for in the use of this parameter. Thus, if V x changes across subjects or between interventions, it will cause problems for the interpretation of this parameter. In contrast, the pons, a smaller and noisier region, whilst being devoid of specific binding is likely to suffer from high variance in BP ND estimates.
Overall, each of the four quantification approaches has their strengths and weaknesses. The overall estimations of V T and BP ND from the 2TCM and SRTM, respectively, lead to good numerical identifiability of these parameters, principally because they are macroparameters, 26 uniquely defined from the models' impulse response functions and reasonably robust in the presence of noise. The shortcomings of these two approaches are that the outcome measures by design contain a component of the off target binding. Nevertheless, if the offtarget binding can be assumed to be unchanged across populations or between interventions, then these are the methods of choice. In contrast, the estimation of V S and V 5 from the 2TCM and spectral analysis rely on the kinetic partitioning of the data through the estimation of microparameters, which leads to the increased problems of numerical identifiability with these outcome measures. Further, they also rely on the interpretation, in the 2TCM case that the second compartment corresponds only to a5 signal and in the case of spectral analysis that all the a5 signal can be kinetically partitioned at one end of the spectrum. Both methods will struggle more with heterogeneity and noise than the macroparameter based methods (Methods I and IV). The strength of Methods II and III is that they try to estimate only the a5 signal.
Thus, the choice of method used in a clinical [ 11 C]Ro15-4513 study should be considered carefully. The ideal situation would be to perform two scans, one with the tracer alone and the second in the presence of a blocking dose of a selective GABA A a5 drug such as Basmisanil; however, this is unlikely to be feasible routinely. If a single scan approach is employed with arterial blood data and one of the more exploratory methods (II and III) is used, then the V T from Method I should also always be presented. This would allow for a consensus analysis to determine whether all the results are consistent. If blood is not acquired and SRTM is used, then one should understand that the interpretation of the outcome measure would rely strongly on the credibility of the assumptions about the off target binding in the particular experimental paradigm under investigation.
In conclusion, we have fully characterised the in vivo selectivity of [ 11 C]Ro15-4513 in humans using heterologous competition data. Overall, the tracer provides a good deal of selectivity for GABA A a5, with a5 representing at least 60-70% of the specific binding in most regions. Nevertheless, the presence of off-target nonselective binding to other GABA A subtypes means that the choice of analysis method and the interpretation of outcome measures must be considered carefully in the context of the experimental design of each [ 
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